Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis acquires Nektar's pulmonary business

This article was originally published in Scrip

Executive Summary

Novartishas acquired Nektar Therapeutics' pulmonary drug delivery business unit for $115 million in cash. The business, which employs around 140 people, will remain in Nektar's facility in San Carlos, California, and specialises in product formulation and delivery. Novartis hopes to use the acquired business to accelerate its pipeline in such diseases as COPD, asthma and cystic fibrosis. The acquisition will also give Novartis complete control of its joint programme with Nektar for the development of a new formulation of tobramycin for the treatment of lung infections associated with cystic fibrosis. As a result, Novartis will not pay Nektar any future milestones or royalties associated with the development project. The deal, which is expected to close by the end of this year, excludes Nektar's inhalation programmes for insulin, vancomycin, ciprofloxacin and amikacin.

You may also be interested in...

Myotec and Hybrid merge to form PsiOxus

Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.

Trophos's MitoCare programme receives €6 million EU funding

A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.

Novartis and Alcon reach compromise to settle merger saga

Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts